Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

134.15 +3.52 (+2.70%)
Streaming Delayed Price Updated: 2:16 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 393,553
Open 132.55
Bid (Size) 134.14 (1)
Ask (Size) 134.34 (2)
Prev. Close 130.63
Today's Range 131.16 - 134.31
52wk Range 55.25 - 159.89
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
From Sarepta Therapeutics, Inc.
Via Business Wire
What Analysts Are Saying About Sarepta Therapeutics Stock
Via Benzinga

Performance

YTD
+39.44%
+39.44%
1 Month
+5.63%
+5.63%
3 Month
+9.22%
+9.22%
6 Month
+72.52%
+72.52%
1 Year
+6.95%
+6.95%

More News

Read More
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics: Q4 Earnings Insights
Via Benzinga
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Top Growth Stock to Buy and Hold for 10 Years
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Via Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in April
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Via Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Via Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
Via The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.